Kymera Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Kymera Therapeutics Inc.
Ownership: Public
Status: Active
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: Watertown
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: KYMR
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001815442
EIN: 81-2992166

Board of directors

Follow this board

Bruce Booth · Director
Since 2023
Elena Ridloff · Director
Since 2023
Felix Baker · Director Overboarded
Since 2024
Gorjan Hrustanovic · Director
Since 2023
Jeffrey W. Albers · Director
Since 2023
Joanna Horobin · Director
Since 2023
John Maraganore · Director Overboarded
Since 2023
Julian Baker · Director Overboarded
Since 2024
Leigh Morgan · Director
Since 2023
Mark N. Lampert · Director
Since 2023
Nello Mainolfi · Director · Chief Executive Officer
Since 2023
Pamela Esposito · Director
Since 2023
Victor Sandor · Director
Since 2023

Chief executives

Nello Mainolfi · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 30 other boards.

Shared director Other board Same sector +14 more in the list below

Prelude Therapeutics Incorporated
via Felix Baker, Julian Baker and Victor Sandor
ACADIA Pharmaceuticals Inc.
via Felix Baker and Julian Baker
BeOne Medicines Ltd.
via Felix Baker and Julian Baker
Bicycle Therapeutics plc
via Felix Baker and Julian Baker
DBV Technologies S.A.
via Felix Baker and Julian Baker
Denali Therapeutics Inc.
via Felix Baker and Julian Baker
Immunic Inc.
via Elena Ridloff and Mark N. Lampert
Immunocore Holdings plc
via Felix Baker and Julian Baker
Incyte Corp.
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc
via Felix Baker and Julian Baker
Kodiak Sciences Inc
via Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc.
via Felix Baker and Julian Baker
Neurogene Inc.
via Felix Baker and Julian Baker
Olema Pharmaceuticals Inc.
via Gorjan Hrustanovic and Mark N. Lampert
Replimune Group Inc.
via Felix Baker and Julian Baker
TScan Therapeutics Inc.
via Felix Baker and Julian Baker
vTv Therapeutics Inc.
via Felix Baker and Julian Baker
ADC Therapeutics SA
via Victor Sandor
AbCellera Biologics Inc.
via Victor Sandor
Agios Pharmaceuticals Inc.
via John Maraganore
Beam Therapeutics Inc.
via John Maraganore
Hemab Therapeutics Holdings Inc.
via John Maraganore
Liquidia Corporation
via Joanna Horobin
MoonLake Immunotherapeutics
via Mark N. Lampert
ProKidney Corp.
via John Maraganore
Rapport Therapeutics Inc.
via John Maraganore
Sionna Therapeutics Inc.
via Bruce Booth
Spyre Therapeutics Inc.
via Jeffrey W. Albers
Takeda Pharmaceutical Company Limited
via John Maraganore
Tectonic Therapeutic Inc.
via Bruce Booth

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $172,499,918; 2 purchases by 1 insider
Sold, last 12 months: $467,562,866; 263 sales by 11 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 4, 2026	Adams Brian Officer (Chief Legal Officer)	Open-market sale	−1,209	$115.55	$139,700
Sep 4, 2026	Adams Brian Officer (Chief Legal Officer)	Open-market sale	−3,025	$116.81	$353,350
Sep 4, 2026	Adams Brian Officer (Chief Legal Officer)	Open-market sale	−2,137	$117.57	$251,247
Jul 27, 2026	Rooney Terence Officer (Chief Medical Officer)	Grant or award	+38,000	—	—
Jul 7, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Option exercise	+50,000	$2.08	$104,000
Jul 7, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−50,000	$119.00	$5,950,000
Jul 1, 2026	Goodman Noah Officer (Chief Business Officer)	Open-market sale	−3,389	$114.29	$387,329
Jul 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Option exercise	+80,000	$2.08	$166,400
Jul 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−1,883	$112.80	$212,411
Jul 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−6,626	$113.98	$755,204
Jul 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−24,105	$114.96	$2,771,002
Jul 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−44,050	$115.69	$5,096,070
Jul 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−3,336	$116.56	$388,841
Jun 30, 2026	Jacobs Bruce N. Officer (Chief Financial Officer)	Option exercise	+61,378	$5.33	$327,145
Jun 30, 2026	Jacobs Bruce N. Officer (Chief Financial Officer)	Open-market sale	−1,500	$110.54	$165,810

Reviews (0)

No reviews yet. Be the first to write one.